Current Geriatrics Reports

, Volume 6, Issue 3, pp 133–138 | Cite as

Prostate Cancer in the Elderly Male: Diagnostic and Management Considerations

  • Marah C. Hehemann
  • Kristin G. Baldea
  • Marcus L. QuekEmail author
Surgical Care for the Geriatric Patient (F Luchette and R Gonzalez, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Surgical Care for the Geriatric Patient


Purpose of Review

Along with an aging US population comes the growing need for clinical guidelines inclusive of and specific to this unique group. Prostate cancer (PCa) is increasingly recognized as a substantial cause of mortality and morbidity in the elderly. This review seeks to address the unmet need for standardized PCa screening and management protocols for geriatric men and to synthesize recommendations based on recent literature.

Recent Findings

Guidelines regarding PCa screening in elderly men are still being optimized, with many organizations moving toward inclusion of pre-screening global health assessment. Physician compliance with screening and treatment of PCa in geriatric patients is suboptimal, despite advanced age being a predictor of advanced disease. Elderly patients may experience treatment-related side effects which differ from their younger counterparts.


Providers treating older men are encouraged to utilize comprehensive health assessments which account for comorbidities, functional status, and global well-being, along with shared decision-making, in determining diagnostic and therapeutic pathways.


Prostate cancer Aged Prostatectomy Risk assessment Surgical care Geriatric care 



Prostate cancer


US Preventive Services Task Force


American Geriatric Society


American Urological Association


National Comprehensive Cancer Network


Prostate-specific antigen


Radical prostatectomy


Radiation therapy


Androgen deprivation therapy


International Society of Geriatric Oncology


External beam radiation therapy


Active surveillance


Compliance with Ethical Standards

Conflict of Interest

Marcus Quek, Kristin Baldea, and Marah Hehemann declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRefGoogle Scholar
  3. 3.
    National Cancer Institute Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts:prostate cancer. 2016. Accessed 16 Dec 2016.
  4. 4.
    Elstad EA, Sheridan SL, Lee JG, Rini C, Earp JA, Brewer NT. Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes. J Behav Med. 2014;37(6):1242–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Wan H, Sengupta M, Velkoff VA, DeBarros KA. U.S. Census Bureau. 65+ in the United States: 2005 (Current Population Reports: p. 23–209). Washington, DC: U.S. Government Printing Office; 2005.
  6. 6.
    Wilt TJ, Dahm P. PSA screening for prostate cancer: why saying no is a high-value health care choice. J Natl Compr Cancer Netw. 2015;13(12):1566–74.CrossRefGoogle Scholar
  7. 7.
    Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med. 2002;162(17):1985–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120–34.PubMedCrossRefGoogle Scholar
  9. 9.
    AGS Choosing Wisely Workgroup. American geriatrics society identifies another five things that healthcare providers and patients should question. J Am Geriatr Soc. 2014;62(5):950–60.CrossRefGoogle Scholar
  10. 10.
    Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419–26.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–13.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly—when to stop? J Urol. 2009;181(4):4.CrossRefGoogle Scholar
  13. 13.
    NCCN Clinical practice guidelines in oncology: Prostate Cancer, version 2. 2017. Available from Accessed 16 Jul 2017.
  14. 14.
    Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists? BJU Int. 2005;95(6):794–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100(6):1254–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Peek ME. Screening mammography in the elderly: a review of the issues. J Am Med Womens Assoc. 2003;58(3):191–8.Google Scholar
  17. 17.
    Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(4):1047–57.PubMedCrossRefGoogle Scholar
  18. 18.
    • Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576–81. Manuscript describing a novel nomogram for estimation of 10-year life expectancy in PCa patients undergoing definitive therapy (RP or RT), thereby identifying those patients believed to benefit most from curative treatment. PubMedCrossRefGoogle Scholar
  19. 19.
    • NCCN. Practice guidelines in oncology: older adult oncology. 2016. Oncologic practice guidelines specific to geriatric patients published by the NCCN. Includes easy-to-follow flow diagrams detailing approach to decision-making in the older adult and comprehensive geriatric assessment. Google Scholar
  20. 20.
    Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015;33(22):2416–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Hutchinson R, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. Testing and referral patterns in the years surrounding the US preventive services task force recommendation against prostate-specific antigen screening. Cancer. 2016;122(24):3785–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Cohn JA, Wang CE, Lakeman JC, et al. Primary care physician PSA screening practices before and after the final U.S. preventive services task force recommendation. Urol Oncol. 2014;32(1):41.e30.CrossRefGoogle Scholar
  23. 23.
    Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014;120(10):1491–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2011;155(11):762–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009;182(5):2242–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology. 2003;62(5):860–5.PubMedCrossRefGoogle Scholar
  29. 29.
    • Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23. Registry study demonstrating the propensity of older men to undergo less invasive treatment of localized PCa. PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Rice KR, Colombo ML, Wingate J, et al. Low risk prostate cancer in men ≥70 years old: to treat or not to treat. Urol Oncol. 2013;31(6):755–60.PubMedCrossRefGoogle Scholar
  31. 31.
    • Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the international society of geriatric oncology. Lancet Oncol. 2014;15(9):404. Most recent SIOG consensus statement on PCa describing assessment of life expectancy, comorbidities, and health status. Authors describe G8 rapid geriatric assessment instrument and stratification of treatment options by level of health impairment. CrossRefGoogle Scholar
  32. 32.
    Daskivich TJ, Fan KH, Koyama T, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013;158(10):709–17.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Pierorazio PM, Humphreys E, Walsh PC, Partin AW, Han M. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int. 2010;106(6):791–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Greco KA, Meeks JJ, Wu S, Nadler RB. Robot-assisted radical prostatectomy in men aged > or =70 years. BJU Int. 2009;104(10):1492–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172(6 Pt 1):2227–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164(6):1929–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346(15):1138–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA. 2000;283(3):354–60.PubMedCrossRefGoogle Scholar
  40. 40.
    • Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. Prospective study demonstrating advanced age as a risk factor for treatment-related sexual, urinary, and bowel sequelae and impact of these effects on patient quality of life and partner satisfaction. PubMedCrossRefGoogle Scholar
  41. 41.
    Mohamad BA, Marszalek M, Brossner C, et al. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol. 2007;51(3):8. discussion 689 CrossRefGoogle Scholar
  42. 42.
    • D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3. Randomized trial demonstrating survival benefit conferred by concomitant short-term ADT with definitive RT versus RT alone in PCa patients with minimal comorbidities. PubMedCrossRefGoogle Scholar
  43. 43.
    D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95.PubMedGoogle Scholar
  44. 44.
    Hoffman KE, Chen MH, Moran BJ, et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer. 2010;116(11):2590–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47(1):103–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Jani AB, Parikh SD, Vijayakumar S, Gratzle J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology. 2005;65(6):1157–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298–304.PubMedCrossRefGoogle Scholar
  48. 48.
    • Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol. 2014;25(11):2134–46. Comprehensive review of evidence-based guidelines for RT in geriatric oncology patients, including men with PCa. PubMedCrossRefGoogle Scholar
  49. 49.
    Martin NE, D'Amico AV. Progress and controversies: radiation therapy for prostate cancer. CA Cancer J Clin. 2014;64(6):389–407.PubMedCrossRefGoogle Scholar
  50. 50.
    Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J Urol. 2016;196(3):721–6.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Watts S, Leydon G, Eyles C, et al. A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. BMJ Open. 2015;5(5):006674.CrossRefGoogle Scholar
  52. 52.
    • Tan HJ, Marks LS, Hoyt MA, et al. The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer. J Urol. 2016;195(6):1724–30. Study evaluating the emotional impact of active surveillance on men with PCa. PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Parker PA, Davis JW, Latini DM, et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016;117(3):469–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Marah C. Hehemann
    • 1
  • Kristin G. Baldea
    • 1
  • Marcus L. Quek
    • 1
    Email author
  1. 1.Department of UrologyLoyola University Medical CenterMaywoodUSA

Personalised recommendations